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Abstract To prevent recurrent ischaemic events, dual an-
tiplatelet therapy (DAPT) is the standard of care after percu-
taneous coronary intervention and in the treatment of acute
coronary syndrome. Recent evidence supports an adjusted
DAPT duration in selected patients.
The current paper aims to encourage cardiologists to ac-
tively search for patients benefiting from either shorter or
prolonged duration DAPT and proposes an algorithm to
identify patients who are likely to benefit from such an
alternative strategy.
Individualised DAPT duration should be considered in
high-risk anatomic and/or clinical subgroups or in patients
at increased haemorrhagic risk with low ischaemic risk.
Both thrombotic and haemorrhagic risk should be assessed
in all patients. In patients undergoing percutaneous coro-
nary intervention, the interventional cardiologist could ad-
vise on the minimal duration of DAPT. However, in con-
trast to the minimum duration of DAPT for stent thrombosis
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prevention, longer duration DAPT is aimed at prevention of
spontaneous myocardial infarction, and not at stent throm-
bosis, and thus the key to success is to treat the patient’s
overall thrombotic risk.
The advice on the duration of DAPT must be docu-
mented in the patient’s records and communicated with the
treating physician and general practitioner. DAPT duration
should be reassessed at least on a yearly basis.
Keywords Acute coronary syndrome · Percutaneous
coronary intervention · Dual antiplatelet therapy
Introduction
Dual antiplatelet therapy (DAPT) with acetylsalicylic acid
in combination with a P2Y12 inhibitor is the standard of
care after an acute coronary syndrome (ACS) and after per-
cutaneous coronary intervention (PCI), to prevent recurrent
ischaemic events such as stent thrombosis. DAPT is rec-
ommended with a class I level of evidence in the current
guidelines [1, 2]. Clopidogrel is first choice in PCI patients
with stable coronary artery disease, whereas the stronger
P2Y12 inhibitors ticagrelor and prasugrel are mainly used
in the ACS setting.
Restenosis rates have dropped dramatically since the in-
troduction of drug-eluting stents (DES). However, first-gen-
eration DES were associated with a slight increase in stent
thrombosis, which is the most feared complication of coro-
nary stenting due to its very high mortality rates. Since the
introduction of second-generation DES, together with the
use of stronger P2Y12 inhibitors, rates of stent thrombosis
have decreased by approximately 50% [3]. Second-genera-
tion DES are now considered superior in all aspects.
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With improvement of the currently available stents, at-
tention has shifted to the downsides of DAPT, such as the
risk of bleeding. Premature discontinuation of clopidogrel
has been shown to be the most important risk factor for
stent thrombosis [4–7]. However, lower complication rates
for coronary stents and increased awareness of bleeding on
DAPT, led cardiologists to question the optimal duration of
DAPT after coronary stenting.
From a mechanical point of view, DAPT is mandatory in
the first months after stent implantation until endotheliali-
sation has been completed. Interestingly, two recent studies
using a new-generation DES demonstrated that DES was
superior to BMS when combined with an ultra-short course
(1 month) of DAPT [8, 9]. As the risk of late stent throm-
bosis is less of a concern with second-generation DES, pro-
longed DAPT is now more aimed at preventing (recurrent)
myocardial infarction (MI) not related to the implanted
stent. Thus, rather than focusing on the stent or the an-
giogram alone, the key to success is to treat the patient’s
overall thrombotic risk.
In the last five years, multiple studies have been pub-
lished comparing duration of DAPT after PCI and in ACS
patients investigating either a shorter or prolonged DAPT
regimen.
Although current ESC guidelines provide backup to in-
dividualise treatment, few patients in daily practice are cur-
rently being treated with a shorter or prolonged DAPT du-
ration in our experience. This article summarises the results
of relevant studies and meta-analysis and provides tools to
individualise the duration of DAPT.
Studies on optimal duration of DAPT
More than 10 randomised controlled trials (RCTs) and an
almost equal number of meta-analyses on optimal DAPT
duration after PCI have been performed. However, results
are not easy to interpret, as length of treatment and com-
parison strategies varied (short versus standard DAPT, pro-
longed vs. standard DAPT and short vs. prolonged). Also,
different definitions were used (e. g. bleeding definitions
TIMI, BARC, STEEPLE, GUSTO).
Shorter duration
In summary, the results of the 5 RCTs and several
meta-analyses indicate that a shorter DAPT regimen
(3–6 months) appears to be as effective as a standard DAPT
duration (12 months) and might even provide a benefit in
terms of bleeding. Of note, these studies included mostly
low-risk patients [10–14]. Interestingly, a recent review
found that 3 months of DAPT appears to be safe in patients
with stable angina undergoing PCI, whereas in ACS pa-
tients, even though predominantly unstable angina/low risk,
it was associated with increased ischaemic risk [15]. Cur-
rently, the REDUCE trial is addressing the issue of reduced
DAPT duration in ACS patients. This physician-initiated,
multicentre trial randomises 1,500 ACS patients treated
with the COMBO stent to 3 vs. 12 months of DAPT [16].
Prolonged dual antiplatelet therapy
The majority of RCTs after prolonged DAPT either failed
to demonstrate a benefit of prolonged treatment or met the
non-inferiority hypothesis. Two studies even suggested po-
tential harm from prolonged DAPT in terms of increased
rates of major bleeding events [17, 18]. Of note, none of the
RCTs demonstrated an increase in fatal bleeding rates with
prolonged DAPT, although the conclusions were limited by
low event rates.
Although no consistent benefit of prolonged DAPT was
observed in the individual RCTs for the ischaemic end-
points, most subsequent meta-analyses using pooled data
did find a significant benefit of prolonged DAPT, but at the
cost of increased bleeding events.
Consequently, it is now believed that DAPT continuation
after 12 months reduces ischaemic events, but at the cost of
increased bleeding rates. In the recent American College of
Cardiology and American Heart (ACC/AHA) focused up-
date on DAPT it was estimated that prolonged DAPT leads
to an absolute decrease in stent thrombosis and ischaemic
complications of 1 to 2% at the cost of an absolute in-
crease in bleeding complications of 1% [2].
Mortality in prolonged DAPT
Several previous studies have raised concerns that seri-
ous bleeding events resulting from prolonged DAPT might
lead to increased rates of all-cause death, thereby offset-
ting the reduction in cardiac death and nonfatal ischaemic
events. This suspicion arose in the DAPT study and in some
[19–22], but not all, meta-analyses [23, 24]. The DAPT
study [25] was by far the largest trial demonstrated a bene-
fit of prolonged DAPT (30 vs. 12 months) in reducing stent
thrombosis (0.4 vs 1.4%, p = 0.001) and major adverse car-
diac and cerebrovascular events (4.3 vs. 5.9%, p = <0.001),
but at the cost of significantly more GUSTO (global utilisa-
tion of streptokinase and t-pa for occluded coronary arter-
ies) moderate or severe bleeding (2.6 vs. 1.6%, p = 0.001).
An unexpected, but important finding was a borderline sig-
nificant (p = 0.05) excess mortality (all-cause death 2.0%
in prolonged DAPT vs. 1.5% in placebo-treated patients)
due to more non-cardiovascular deaths [25, 26].
The meta-analysis in the ACC/AHA focused update ad-
dressed this topic and found “weak evidence” of increased
mortality with prolonged DAPT in those RCTs that suc-
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cessfully achieved their predefined enrolment target [3].
Another analysis in this review suggested increased mortal-
ity with prolonged DAPT in patients without prior history
of ACS but not in patients with a history of prior ACS.
Prolonged DAPT after MI
Most notably, patients who have had an MI are deemed
at risk for recurrent ischaemic events. Unfortunately, few
studies focused on this specific patient group.
The PEGASUS is a double-blind RCT including 21,162
patients with a previous myocardial infarction and addi-
tional ischaemic risk factors [27]. In patients treated with
prolonged DAPT with ticagrelor an absolute risk reduction
of cardiovascular death, myocardial infarction and stroke
of 1.3% at the cost of an equally increased risk of major
bleeding events was found. All-cause death did not differ
significantly.
Udell et al. analysed in a recent meta-analysis in pa-
tients with previous MI either treated medically or managed
with PCI, whether prolonged DAPT after one year (mean
difference in achieved duration of DAPT 30 months) is
beneficial. They found a reduction in major adverse cardio-
vascular events including stent thrombosis (6.4 vs. 7.5%;
risk ratio, RR 0.78, p = 0.001) and cardiovascular death
(2.3 vs. 2.6%; RR 0.85, p = 0.03), but no significant effect
on overall mortality (RR of 0.92 (95% CI 0.83–1.03; p =
0.13)) [24]. An increased rate of major bleeding events was
observed (1.85 vs. 1.09%; RR 1.73, p = 0.004), but not of
fatal bleeding events.
Overall, it is demonstrated that the benefit of prolonged
DAPT in reducing future ischaemic events is much stronger
after MI as compared to in stable coronary artery disease
(SCAD) patients [28].
Interpretation
Conceptually, some of the foregoing conclusions are dif-
ficult to interpret. How can shorter-duration DAPT be as
effective as the ‘standard regimen’, when on the other
hand extended-duration DAPT reduces recurrent ischaemic
events, including stent thrombosis?
Moreover, the paradigm that platelet inhibitors reduce
thrombotic risk, but increase bleeding, in our opinion still
holds true for the various strategies. As this principle was
observed in studies after prolonged DAPT duration, but not
in studies after shorter duration, this observed asymmetrical
treatment effect might be due to the low event rates, patient
selection or chance.
Indeed, it proves useful to look in detail at these studies.
With regard to stent thrombosis, an important endpoint, all
5 studies investigating a shorter DAPT duration are ham-
pered by very low (<50% of expected) event rates with
stent thrombosis rates varying from 1 to 6 per treatment
arm. Therefore, the outcomes regarding stent thrombosis
should be interpreted with caution.
With regard to prolonged DAPT, it is important to ac-
knowledge that in most trials patients were randomised after
the first year and only if they did not have any major bleed-
ing events. On the other hand, this reflects clinical practice,
in which the decision to extend DAPT after a year can
be revised at any stage should haemorrhagic or ischaemic
events occur.
Because both ischaemic outcomes and bleeding events
are reported in most studies, in some studies even as a com-
posite endpoint, it is difficult to know how to weigh haemor-
rhagic risks against ischaemia risks. The impact of bleeding
events should, however, not be underestimated. It is a strong
predictor of mortality; in some studies even stronger than
myocardial infarction [23, 29].
The ADAPT-DES study provided important detailed in-
formation on this subject [30]. The authors demonstrated
that stent thrombosis, although infrequent with 0.9%, was
associated with very high mortality rates ranging from 15
to 38% (the latter for early stent thrombosis). Spontaneous,
not stent thrombosis related MI was less frequently fatal
(mortality rates ranging from 0.8–7.5%). Mortality rates
after clinically relevant bleeding events were comparable
with spontaneous MI. In conclusion, as there is evidence of
potential harm associated with prolonged DAPT, it should
only be considered in carefully selected patients at substan-
tially high ischaemic and low haemorrhagic risk.
Current guidelines
The 2014 European Society of Cardiology (ESC) guideline
on myocardial revascularisation advises treating patients
with SCAD with DAPT for 6 months after DES implan-
tation (class I level B) [1]. Shorter DAPT duration may
be considered in patients with a high haemorrhagic risk
(IIb, A), whereas the guideline advises that DAPT may be
used for more than 6 months in patients at high ischaemic
and low haemorrhagic risk (IIb, C). The 2015 ESC guide-
line on non-ST-segment elevation ACS recommends con-
sidering a shorter DAPT duration of 3–6 months after DES
implantation in patients deemed at a high haemorrhagic
risk (IIb, A) [31]. This is remarkable, because evidence
is based on studies that included predominantly low-risk
patients with SCAD. Furthermore, the guideline includes
a IIb (level A) recommendation for continuing DAPT be-
yond 1 year in selected patients with ACS ‘after careful
assessment of the ischaemic and haemorrhagic risks of the
patient’. However, it does not specify how we can identify
these patients.
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The ACC/AHA Focused Update provides an excellent
overview of the relevant studies. However, the recommen-
dations are essentially not very different from current guide-
lines and again lack specific guidance on identifying the
patients suitable for individualised treatment [2, 3]. In ACS
patients, either prolonged or shorter DAPT ‘may be reason-
able’, (IIB) depending on the presence or absence of high
haemorrhagic risk. Importantly, the authors consider this
regardless of treatment strategy.
For patients with SCAD, the guideline recommends con-
tinuing DAPT in DES-treated patients after 6 months if
there is ‘no high risk of bleeding and no significant overt
bleeding on DAPT’. Interestingly, ischaemic risk is not con-
sidered. In our interpretation of the currently available stud-
ies, however, evidence for prolonged DAPT, particularly
after one year, in patients with SCAD is weak, especially
in the absence of previous MI. Prolonged DAPT may even
cause harm.
DAPT duration: the right strategy for the right
patient
In conclusion, the aforementioned studies and reviews sug-
gest that a minimum duration of six or even three months
is effective in low-risk patients with SCAD after second-
generation DES implantation, whereas in ACS patients,
extension of DAPT beyond 12 months appears to be ben-
eficial only in selected subgroups, most notably patients
with prior MI.
The large RCTs and high quality meta-analyses do, how-
ever, not support one new standard DAPT duration in all
patients. They rather support a personalised treatment in
which the duration of DAPT is determined on an individual
patient basis, reflecting an accurate trade-off between the
individual ischaemic and haemorrhagic risks.
Use of risk scores
Risk scores may aid in this decision-making. Previously,
several clinical patient characteristics (e. g. ACS, diabetes,
impaired left ventricular function), as well as procedural
(e. g. dissection, bifurcation stenting) and angiographic fac-
tors (e. g. undersizing of the stent, small stent diameter)
have been identified as risk factors for stent thrombosis [4,
32, 33]. As demonstrated in the DAPT study, however, ap-
proximately 50% of recurrent atherothrombotic events are
not related to stent thrombosis. Hence, the patient’s over-
all ischaemic risk should be considered when it comes to
longer duration of DAPT.
Traditionally used scores to assess ischaemic risk include
the TIMI and GRACE risk score [34, 35]. While these risk
scores are very useful in the initial assessment of ischaemic
risk and hence in guiding treatment and timing of coronary
angiography, the clinical applicability in the outpatient set-
ting is limited because of the parameters used.
Recently, the DAPT risk score was published [32]. Al-
though the DAPT score helps us to identify patients who
are likely to benefit from or who are likely to be harmed by
prolonged DAPT, it must be noted that this score has yet to
be validated prospectively.
Bleeding risk can also be assessed by commonly used
risk scores such as the CRUSADE and the HAS-BLED
scores [36, 37]. However, the applicability of these risk
scores is also limited. The CRUSADE score was designed
for in-hospital use in patients with non-ST-segment-eleva-
tion myocardial infarction, whereas the HAS-BLED score
is used in patients with atrial fibrillation. Furthermore, it
must be noted that the predictive value of the HAS-BLED
score is limited. The recently updated ESC atrial fibrilla-
tion guideline acknowledges that the HAS-BLED score is
merely a tool to identify modifiable risk factors [38].
Another difficulty in clinical daily practice is that some
risk factors are associated with both haemeorrhagic and
ischaemic risk (e. g. renal function, age). Interestingly, the
DAPT study found that higher age increased haemorrhagic
risk more than ischaemic risk [32].
Selecting the right patient for the right therapy
So here we are. Decision-making for DAPT duration has
never been so complex, but it is clear that a one-size-fits-all
approach is outdated. However, we currently lack a compre-
hensive risk score to identify ischaemic and haemorrhagic
risk in patients with coronary artery disease. The DAPT
score might prove a very useful tool for prolonged DAPT
but its validity has yet to be proven prospectively. Other
existing risk scores focus more on the patient’s initial risk
rather than on the long-term risk. Although we encourage
identification and documentation of the patient’s risk with
these risk scores, a different approach is needed to establish
the best strategy in individual patients.
Therefore, we propose to start individualised therapy
with a few well-defined and recognisable patient groups
as set out below. Although this is a simplification of risks,
we believe that there is sufficient evidence to individualise
treatment duration in these patients on the two sides of the
spectrum. Tables 1, 2 and 3 describe the three patient groups
that are likely to benefit from an alternative strategy.
The algorithms are based on the standard treatment reg-
imen according to current ESC guidelines, i. e. 6 months
of DAPT after elective PCI for SCAD or 12 months after
ACS. Shorter duration is defined as three months in SCAD
(or 1 month if an ultrashort duration is indicated) or six
months after ACS. Prolonged DAPT can be continued for
multiple years (in line with the DAPT study and the PEGA-
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Table 1 Proposed treatment algorithm for reduced DAPT duration
Shorter DAPT duration
(3 months in stable CAD; 6 months after ACS)
Single-vessel PCI
And
One of the following criteria for high bleeding risk:
– Prior intracranial haemorrhage
– Recent major bleeding
– (N)OAC long-term therapy
– Frailty and age >75 years
– Malignancy
DAPT dual antiplatelet therapy, CAD coronary artery disease,
ACS acute coronary syndrome, PCI percutaneous coronary
intervention, (N)OAC (Non-vitamin-K) oral anticoagulant
Table 2 Proposed treatment algorithm for ultra-short DAPT duration
Ultra-short DAPT duration
(1 month)
Single-vessel PCI for stable CAD
And
Use of latest generation stent with CE approval for 1 month of DAPT
use (e. g. Biofreedom or Endeavor)
And
Patient is deemed to be at very high bleeding riskaor scheduled for
urgent surgery
DAPT dual antiplatelet therapy, CAD coronary artery disease,
CE Conformité Européenne
aVery high bleeding risk: risk factors mentioned in Table 1 and
additional risk factors at physician’s discretion
Table 3 Proposed treatment algorithm for prolonged DAPT duration
Prolonged DAPT duration
Presentation as ACS or previous history of ACS; regardless of treat-
ment strategy
And
No major bleeding events during the first course of DAPT and no
long-term (N)OAC
And
One of the following additional criteria for high thrombotic risk:
– prior stent thrombosis
– recurrent MI
– diabetes mellitus
– peripheral artery disease
– multivessel coronary disease
– complex coronary stentinga
DAPT dual antiplatelet therapy, ACS acute coronary syndrome,
MI myocardial infarction, (N)OAC (Non-vitamin-K) oral anticoagulant
aLeft main stent, bifurcation stenting, long or overlapping stents, last
remaining vessel, venous graft percutaneous coronary intervention
SUS study), provided that this strategy is evaluated annually
and amended if adverse events, such as bleeding events, are
encountered. There are currently no data to support contin-
uation of DAPT after three years.
We have sought to describe clear and undisputed sub-
groups. We only included risk factors which have repeat-
edly been shown to be risk factors for either haemorrhagic
or recurrent ischaemic events [2, 4, 28, 32, 39, 40]. How-
ever, it is important to emphasise that this is not a final or
static algorithm. Its aim is to identify, on both sides of the
spectrum, patient groups that are likely to benefit from an
alternative strategy. Patients not fitting the descriptions in
the tables – or meeting criteria compatible with both high
hameorrhagic and thrombotic risk – should be treated with
standard DAPT duration. On the other hand, we obviously
encourage alternative strategies in individual patients when
this is motivated and documented.
To illustrate decision-making in clinical practice we have
included two hypothetical cases.
Case 1: high ischaemic risk, prolonged dual antiplatelet
therapy (DAPT)
A 52-year-old man, known diabetic and smoker, is admitted
with an anterior ST-segment-elevation myocardial infarc-
tion (STEMI) for which he undergoes successful primary
percutaneous coronary intervention (PCI) with implantation
of two stents. There is diffuse moderate disease in the right
and circumflex coronary artery for which no intervention
is needed at present. The angiogram of his femoral artery
taken at the end of the procedure also showed peripheral
artery disease. There is no bleeding history. The interven-
tional cardiologist notes in his PCI report that this patient
might be suitable for prolonged DAPT.
He is seen at the clinic for follow-up at three months
and again at one year and remained symptom free from
a cardiac point of view. There are no bleeding events during
the first year. His cardiologist discusses the considerations
for prolonged DAPT with him and they decide to continue
the DAPT. He will come back after one year and if the
DAPT is well tolerated, it might be reasonable to continue
DAPT for even longer.
● Ischaemic risk: High (multivessel disease), diabetes, pe-
ripheral artery disease
● Haemorrhagic risk: Low (no bleeding history, relatively
young age)
Case 2: high haemorrhagic risk, shorter dual antiplatelet
therapy (DAPT)
A 67-year-old woman with osteoporosis and hypertension
presents to the outpatients’ clinic with a 6-month history
of angina. Coronary angiography demonstrated a narrow-
ing in the mid-portion of the right coronary artery. She
subsequently underwent a percutaneous coronary inter-
vention during which a drug-eluting stent is implanted,
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with excellent result. There is only minor disease in the
left coronary artery. Three months later, she is admitted
with a gastro-intestinal bleeding with a three point drop
in haemoglobin. Colonoscopy and computed tomography
demonstrate a T2N0M0 tumour for which she will need
surgery. The surgeon discusses the discontinuation of DAPT
with her cardiologist and in light of the low ischaemic risk
and the high haemorrhagic risk they agree to discontinue
the P2Y12 inhibitor. Aspirin should be continued.
● Ischaemic risk: Low (PCI for stable CAD, no other high-
risk ischaemic features)
● Haemorrhagic risk: High (recent gastro-intestinal bleed-
ing; active malignancy)
Future perspective and implementation in daily practice
Algorithms like the DAPT-scores should be tested in future
prospective studies to prove their validity and applicability.
When we test such strategies, it is important to acknowledge
a distinction according to clinical presentation: SCAD or
ACS patients.
We believe in an important advisory role for the inter-
ventional cardiologist. The interventional cardiologist who
performs the PCI, knows the angiographic complexity and
results of the procedure and is therefore best equipped to
determine the minimum DAPT duration to be incorporated
in the PCI report. For patients who are conservatively man-
aged, the treating physician is in the lead.
In all scenario’s, it is essential that the recommended
DAPT duration and preferred P2Y12 inhibitor are included
in the discharge letter. This advice should be communicated
to the referring district hospitals, if applicable, and to the
patient’s general practitioner.
Obviously, DAPT duration is not a static advice and it
can be revised at any time during the patient’s follow-up
(e. g. recurrent myocardial infarct, stroke or bleeding com-
plications). This implies that there is an important role for
the cardiologists who provide clinical follow-up for their
patient in clinic. At least, the DAPT duration should be
rediscussed at the time of the first follow-up visit after dis-
charge and at every annual follow-up.
With this paper, we intend to increase awareness and
emphasise the importance of an individualised treatment
strategy in patients undergoing PCI or presenting with ACS,
regardless of treatment strategy.
We hope to encourage cardiologists in the Netherlands
and abroad to join us in this strategy. The ultimate goal is to
offer a personalised DAPT recommendation to any patient
suffering from ACS or undergoing PCI. Hopefully, with the
help of and in cooperation with the Netherlands Society for
Cardiology (NVVC) and its working groups, we will be
able to implement personalised DAPT duration in the near
future.
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